A double-blind, randomized, placebo-controlled study of the efficacy, safety and tolerability of 8-week treatment of Rozerem [ramelteon] 8mg (QHS) in sleep-disturbed, community-dwelling, mild to moderately severe Alzheimer's disease subjects
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 19 Jan 2010
At a glance
- Drugs Ramelteon (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- 28 Jun 2006 New trial record.